Journal List > Allergy Asthma Respir Dis > v.6(1) > 1095718

Allergy Asthma Respir Dis. 2018 Jan;6(1):68-71. Korean.
Published online Jan 31, 2018.  https://doi.org/10.4168/aard.2018.6.1.68
© 2018 The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology
Successful desensitization to fluconazole induced delayed hypersensitivity: A case report
Yeon-Jeong Heo,1 Seung-Woo Park,1 Kyu-Sun Lee,1 Hye-Ryun Kang,2 and Jae-Woo Kwon1,3
1Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea.
2Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
3Department of Allergy and Clinical Immunology, Kangwon National University Hospital, Chuncheon, Korea.

Correspondence to: Jae-Woo Kwon. Department of Internal Medicine, Kangwon National University Hospital, 156 Baengnyeong-ro, Chuncheon 24289, Korea. Tel: +82-33-258-9370, Fax: +82-33-258-2404, Email: legent@hanmail.net
Received April 15, 2017; Revised August 02, 2017; Accepted September 08, 2017.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).


Abstract

Fluconazole is a triazole-based first-generation antifungal agent and has excellent effects on candidiasis and cryptococcosis. Hypersensitivity has been reported as a side effect of fluconazole. A 76-year-old female patient used fluconazole for consolidation therapy for cryptococcal meningitis, but showed delayed hypersensitivity with skin rashes and itching sensation of the whole body. For desensitization, was attempted by administering 12-step, 1:1 fluconazole solutions were administered intravenously at sequentially increasing infusion rates. After successful quick desensitization to fluconazole, fluconazole was continuously used as a consolidation therapy for cryptococcal meningitis. We herein report a case of delayed hypersensitivity reaction to fluconazole in consolidation therpy with cryptococcal meningitis who successfully completed desensitization.

Keywords: Desensitization; Fluconazole

Figures


Fig. 1
Clinical features of the fluconazole-induced delayed type hypersensitivity. There was diffuse patch eruption involving the trunk (A) and extremities (B) with itching and blanching, which continued for several days.
Click for larger imageDownload as PowerPoint slide

Tables


Table 1
The preparation of 1-bottle solution used in the rapid desensitization protocol
Click for larger imageClick for full tableDownload as Excel file


Table 2
Desensitization protocol used in the current case of the fluconazole-induced delayed hypersensitivity
Click for larger imageClick for full tableDownload as Excel file

References
1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:e1–e50.
2. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010;50:291–322.
3. Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis 1988;157:178–180.
4. Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:481–489.
5. Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, et al. Desensitization in delayed drug hypersensitivity reactions: an EAACI position paper of the Drug Allergy Interest Group. Allergy 2013;68:844–852.
6. Yoshizawa S, Yasuoka A, Kikuchi Y, Honda M, Gatanaga H, Tachikawa N, et al. A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S. Ann Allergy Asthma Immunol 2000;85:241–244.
7. Kim S, Lim KH, Kang MG, Park HK, Cho SH, Min KU, et al. Successful desensitization of trimethoprim-sulfamethoxazole in Stenostrophomonas maltophilia osteomyelitis. Allergy Asthma Respir Dis 2014;2:218–221.
8. Lee AR, Kim SJ, Kim J, Park JH, Lee JK, Kim JY, et al. Successful desensitization for antitubercular drugs. Allergy Asthma Respir Dis 2013;1:395–399.
9. Yoon D, Ahn H, Kim SY, Hwang SJ, Park HK, Kang HR. Successful rapid desensitization to trimethoprim-sulfamethoxazole-induced delayed hypersensitivity. Allergy Asthma Respir Dis 2015;3:155–158.
10. Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology 2004;209:29–32.
11. Craig TJ, Peralta F, Boggavarapu J. Desensitization for fluconazole hypersensitivity. J Allergy Clin Immunol 1996;98:845–846.
12. Jariwala S, Vernon N, de Vos G. A novel method of desensitization for fluconazole hypersensitivity in a patient with AIDS. Ann Allergy Asthma Immunol 2011;106:542–543.
13. Randolph C, Kaplan C, Fraser B. Rapid desensitization to fluconazole (Diflucan). Ann Allergy Asthma Immunol 2008;100:616–617.
14. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005;209:209–216.
15. Hassoun-Kheir N, Bergman R, Weltfriend S. The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions. Int J Dermatol 2016;55:1219–1224.
16. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12 Suppl 3:S318–S326.